Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sakurasaku Plus CoTSE:7097 -1.45%71 Debt-to-EBITDA is 1.79 as of Jan. 2026, which is 28% below its 10-year median of 2.48. GuruFocus rates TSE:7097 with a GF Score™ of 71/100 and a GF Value™ of 円1,604.17 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 478 Healthcare Providers & Services companies, Sakurasaku Plus Co ranks worse than 61.09% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sakurasaku Plus Co's Debt-to-EBITDA or its related term are showing as below:
TSE:7097'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.62 Med: 2.48 Max: 5.64
Current: 3.15
During the past 8 years, the highest Debt-to-EBITDA Ratio of Sakurasaku Plus Co was 5.64. The lowest was 1.62. And the median was 2.48.
TSE:7097's Debt-to-EBITDA is ranked worse than 61.09% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs TSE:7097: 3.15
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sakurasaku Plus Co Debt-to-EBITDA Related Terms
Sakurasaku Plus Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sakurasaku Plus Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7097 vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Sakurasaku Plus Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakurasaku Plus Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sakurasaku Plus Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sakurasaku Plus Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jan. 2026) EBITDA data.
Sakurasaku Plus Co (TSE:7097) has a Debt-to-EBITDA of 1.79 as of Jan. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sakurasaku Plus Co. This is 28% below median its historical median of 2.48. Over the past decade, Sakurasaku Plus Co's Debt-to-EBITDA has ranged from 1.62 to 5.64. According to the industry distribution chart, Sakurasaku Plus Co ranks #292 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 61.1%.
Is Sakurasaku Plus Co's Debt-to-EBITDA too high?
Sakurasaku Plus Co's current Debt-to-EBITDA of 1.79 is 28% below median its 10-year median of 2.48. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 5.64. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Sakurasaku Plus Co's value of 1.79 is 18.5% below this industry median. Based on the distribution chart, Sakurasaku Plus Co ranks #292 out of 478 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sakurasaku Plus Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakurasaku Plus Co's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sakurasaku Plus Co ranks #292 out of 478 companies for Debt-to-EBITDA. This places Sakurasaku Plus Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. Sakurasaku Plus Co's value of 1.79 is 18.5% below this benchmark. Historically, Sakurasaku Plus Co's own Debt-to-EBITDA has ranged from 1.62 to 5.64 over the past decade. While the company's 10-year median is 2.48 vs. the industry median of 2.20, Sakurasaku Plus Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sakurasaku Plus Co's current Debt-to-EBITDA of 1.79 is 18.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sakurasaku Plus Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakurasaku Plus Co's current Debt-to-EBITDA is 1.79, which is 28% below median its own 10-year median of 2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakurasaku Plus Co stock overvalued right now?
Based on GuruFocus' analysis, Sakurasaku Plus Co (TSE:7097) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,604.17, compared to a current price of 円2,725.00 — trading 69.9% above its estimated fair value. The current Debt-to-EBITDA is 1.79, which is 28% below median its 10-year median of 2.48 and 18.5% below the Healthcare Providers & Services industry median of 2.20. Sakurasaku Plus Co's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sakurasaku Plus Co (TSE:7097), the current Debt-to-EBITDA is 1.79 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakurasaku Plus Co (TSE:7097) Overvalued in 2026?
Based on GuruFocus' analysis, Sakurasaku Plus Co stock appears to be overvalued.
The current stock price of 円2,725.00 is trading 69.9% above its estimated GF Value™ of 円1,604.17.
GuruFocus considers Sakurasaku Plus Co to be Significantly Overvalued.
Key valuation signals for TSE:7097:
Debt-to-EBITDA: 1.79 (28% below median its 10-year median of 2.48)
GF Value™: 円1,604.17 vs. price of 円2,725.00 (69.9% above fair value)
Industry Position: 18.5% below the Healthcare Providers & Services median (#292 of 478)
No single metric tells the full story. See the TSE:7097 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakurasaku Plus Co Ltd is engaged in the operation and use of childcare daycare centers. The company also provides real estate brokerage and management services. The Group operates in a single segment, the children and childcare support business.
71GF Score
Get the complete analysis for TSE:7097
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7097 has been successfully added to your 
